Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OMP-59R5: Phase Ib/II amended

OncoMed amended the double-blind, U.S. Phase Ib/II ALPINE trial of IV OMP-59R5 in about 154 patients with stage IV pancreatic cancer to include Abraxane nab-paclitaxel

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE